Influence of Preoperative Immunomodulation by Oral Impact on Postoperative Complications Following Cystectomies & Nephrectomies

ConditionUrological Manifestations

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorCentre Hospitalier Intercommunal Robert Ballanger

About this trial

any studies have shown the benefit of perioperative Oral Impact immunomodulation in gastrointestinal, ENT, gynecological and cardiac surgery. Studies in major Urological surgery are rare and not very contributory. The expected benefit is a reduction in postoperative complications and the average length of stay.

Eligibility criteria

Qualifiers

18 years of age and older

Scheduled major urological surgery: scheduled: cystectomy, nephrectomy, other laparotomies.

Having expressed their free and informed consent.

Affiliated to a social security scheme

Disqualifiers

Immune deficiency.

HIV infection.

Curative surgery for chronic urinary tract infection.

Urgent surgery.

Trial design

Treatments tested in this trial

ORAL IMPACT treatment
control

Treatment groups

214 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Centre Hospitalier Intercommunal Robert Ballanger

Lead sponsor

Source ClinicalTrials.gov